Aug 17, 2023 5:30pm EDT Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
Aug 09, 2023 5:30pm EDT Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
Jun 15, 2023 7:25am EDT FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients
